Lindahl advises Dicot Pharma in a rights issue of approximately SEK 231 million

The issue was oversubscribed with a final outcome of approximately 134 per cent and included both new and existing investors. The proceeds will primarily be used to conduct the planned clinical Phase 2b study with the drug candidate LIB-01, which is intended to commence during the second half of 2026. Dicot Pharma is developing LIB-01 as a new treatment concept for erectile dysfunction. LIB-01 demonstrates a long-acting effect on erectile function and a novel mechanism of action that differs from how current erectile dysfunction medications work.

The capital raise provides Dicot Pharma with the conditions to continue the development of LIB-01 through the clinical Phase 2b study, including pre-clinical studies ahead of Phase 3.

Lindahl's team consisted of Mattias Prage and Michaela Larsson.

About our client Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which is expected to become a treatment for erectile dysfunction and premature ejaculation. The ambition is to create a medication with a significantly longer duration of action and far fewer side effects compared to the drugs currently available on the market. Today, over 500 million men suffer from these sexual dysfunctions, and the market is valued at approximately SEK 80 billion. Dicot Pharma's business model is to continuously evaluate industrial and financial partnerships during the clinical development process, with a view to bringing the candidate to commercialisation on the global market. Dicot Pharma AB is listed on Nasdaq First North.